15.65
-0.55 (-3.40%)
| Previous Close | 16.20 |
| Open | 16.11 |
| Volume | 420,414 |
| Avg. Volume (3M) | 549,430 |
| Market Cap | 945,275,648 |
| Price / Sales | 650.22 |
| Price / Book | 3.22 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BTIG, 347.28%) | Buy |
| Median | 56.50 (261.02%) | |
| Low | 43.00 (Deutsche Bank, 174.76%) | Buy |
| Average | 56.50 (261.02%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 15.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 26 Sep 2025 | 43.00 (174.76%) | Buy | 16.24 |
| BTIG | 16 Sep 2025 | 70.00 (347.28%) | Buy | 14.82 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Oct 2025 | Announcement | Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 |
| 03 Oct 2025 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
| 15 Sep 2025 | Announcement | Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |